{"preliminary_commentary":{"by_channel":{"x_thread":75,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01348217\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"locally advanced or inoperable esophageal carcinoma","name":"CONCORDE","nct_id":"NCT01348217","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=concorde-nct01348217. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CONCORDE","arms":[{"description":"Conformal 3D Radiotherapy with \" ENI \"-type prophylactic irradiation of the lymph nodes:\n\n1. Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)\n2. Boost 10 Gy in 5 fr: PTV = +1cm.\n3. Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)","label":"ARM A","type":"ACTIVE_COMPARATOR"},{"description":"Conformal 3D Radiotherapy with \" ENI \"-type prophylactic irradiation of the lymph nodes:\n\n1. 40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)\n2. Boost 26 Gy in 13 fr: PTV = +1cm.\n3. Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43).","label":"ARM B","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute, France","UNICANCER","SFRO:French Society of Radiation Oncology","Federation Francophone de Cancerologie Digestive"],"completion_date":{"date":"2018-12-17","type":"ACTUAL"},"conditions":["Esophageal Cancer"],"enrollment":{"count":196,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Conformal 3D Radiotherapy with \" ENI \"-type prophylactic irradiation of the lymph node","otherNames":[],"type":"RADIATION"},{"name":"Boost","otherNames":[],"type":"RADIATION"},{"name":"Boost","otherNames":[],"type":"RADIATION"},{"name":"chemotherapy: FOLFOX 4","otherNames":[],"type":"DRUG"}],"last_update":"2020-01-27","lead_sponsor":"Centre Georges Francois Leclerc","official_title":"Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2011-06-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Evaluate the rate of acute toxicity leading to cessation or temporary interruption of treatment of more than a total of 14 days or of 7 consecutive days during the whole treatment.","timeFrame":"end of phase II (january 2014)"},{"measure":"Evaluate the rate of completes endoscopic response at 3 months","timeFrame":"for each patient 3 months after the end treatment"},{"measure":"Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement)","timeFrame":"after the end of phase III in january 2015 (anticipated)"}],"references":[{"citation":"Bednarek C, Crehange G, Quivrin M, Cueff A, Vulquin N, Chevalier C, Cerda T, Petegnief Y, Mazoyer F, Maingon P, Bosset JF, Servagi Vernat S. Mapping of failures after radiochemotherapy in patients with non-metastatic esophageal cancer: A posteriori analysis of the dose distribution in the sites of loco-regional relapse. Radiother Oncol. 2015 Aug;116(2):252-6. doi: 10.1016/j.radonc.2015.07.019. Epub 2015 Jul 27.","pmid":"26228970","type":"DERIVED"}],"start_date":{"date":"2011-05-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus","url":"https://clinicaltrials.gov/study/NCT01348217"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/concorde-nct01348217"}